Background: Few data are available on the safety and efficacy of infliximab biosimilar CT-P13 in patients with ulcerative colitis and Crohn's disease.
The PROSIT-BIO study of infliximab biosimilar (Remsima/Infliximab) was conducted at 49 centers in Italy in patients with ulcerative colitis (UC)...
Hospira has announced the results of a clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety...
New data presented at the 2016 United European Gastroenterology (UEG) Week show that a switch to biosimilar infliximab (CT-P13)(Inflectra) from...
Napp Pharma has launched Remsima (infliximab biosimilar) in the United Kingdom at the same time as Hospira launched Inflectra (infliximab...
Celltrion, Inc. has announced that the company has completed Phase III clinical trial for �Remsima SC�, the subcutaneous (SC) version...
Napp Pharmaceuticals has secured exclusive rights to distribute in the UK, Remsima (infliximab-biosimilar), from Celltrion being the biosimilar version of...
Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn's disease (CD), and ulcerative colitis.
The infliximab originator's patent recently expired, leading to the production of biosimilar versions of the drug.
Celltrion Healthcare announced that the European Commission has approved Remsima SC (CT-P13 SC, biosimilar infliximab) for patients with RA. Remsima...